91 related articles for article (PubMed ID: 2323681)
1. Thrombin activity and oral anticoagulant therapy: a further evaluation.
Marongiu F; Sorano GG; Mameli G; Mamusa AM; Cambuli AB; Conti M; Cadoni MC; Balestrieri A
Haemostasis; 1990; 20(1):63-4. PubMed ID: 2323681
[No Abstract] [Full Text] [Related]
2. A thrombin assay based upon the release of fibrinopeptide A from fibrinogen: definition of a new thrombin unit.
Lewis SD; Shafer JA
Thromb Res; 1984 Jul; 35(2):111-20. PubMed ID: 6474412
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of thrombin activity by immunoquantitation of fibrinopeptide A generation.
Emanuele RM; Fareed J; Walenga JM; Hoppensteadt D; Fenton JW
Semin Thromb Hemost; 1986 Oct; 12(4):318-23. PubMed ID: 3787269
[No Abstract] [Full Text] [Related]
4. [Role of chromogenic substrates in the study of blood coagulation and fibrinolysis].
Rutllant ML
Sangre (Barc); 1978; 23(6):858-63. PubMed ID: 311079
[No Abstract] [Full Text] [Related]
5. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin.
Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T
Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959
[TBL] [Abstract][Full Text] [Related]
6. Substitution of tyrosine for phenylalanine in fibrinopeptide A results in preferential thrombin cleavage of fibrinopeptide B from fibrinogen.
Rooney MM; Mullin JL; Lord ST
Biochemistry; 1998 Sep; 37(39):13704-9. PubMed ID: 9753458
[TBL] [Abstract][Full Text] [Related]
7. Fibrinogen Milano IV, another case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A alpha 16 Arg----His).
Bögli C; Hofer A; Baudo F; Redaelli R; Furlan M
Haemostasis; 1992; 22(1):7-11. PubMed ID: 1521828
[TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Bergamo I (A alpha 16Arg----Cys): susceptibility towards thrombin following aminoethylation, methylation or carboxamidomethylation of cysteine residues.
Reber P; Furlan M; Beck EA; Finazzi G; Buelli M; Barbui T
Thromb Haemost; 1985 Aug; 54(2):390-3. PubMed ID: 4082078
[TBL] [Abstract][Full Text] [Related]
9. The generation of fibrinopeptide A in clinical blood samples: evidence for thrombin activity.
Nossel HL; Ti M; Kaplan KL; Spanondis K; Soland T; Butler VP
J Clin Invest; 1976 Nov; 58(5):1136-44. PubMed ID: 993337
[TBL] [Abstract][Full Text] [Related]
10. [Functional state of the anticoagulation system during intravenous administration of fibrin monomer].
Kudriashov BA; Molchanova LV; Kalishevskaia TM; Bazaz'ian GG; Pastorova VE; Sytina NP
Vopr Med Khim; 1969; 15(5):483-6. PubMed ID: 5368085
[No Abstract] [Full Text] [Related]
11. Congenital dysfibrinogenemia: fibrinogen Lille.
Denninger MH; Finlayson JS; Reamer LA; Parquet-Gernez A; Goudemand M; Menache D
Thromb Res; 1978 Sep; 13(3):453-66. PubMed ID: 741439
[No Abstract] [Full Text] [Related]
12. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution.
Borrell M; Vila L; Solá J; Coll I; Fontcuberta J
Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678
[TBL] [Abstract][Full Text] [Related]
13. Progress in the measurement of circulating fibrinogen derivatives.
Wilner GD
Prog Clin Pathol; 1984; 9():15-45. PubMed ID: 6229812
[No Abstract] [Full Text] [Related]
14. Fibrinopeptide A release is necessary for effective B:b interactions in polymerisation of variant fibrinogens with impaired A:a interactions.
Soya K; Terasawa F; Okumura N
Thromb Haemost; 2013 Feb; 109(2):221-8. PubMed ID: 23238100
[TBL] [Abstract][Full Text] [Related]
15. [Interaction of a peptide inhibitor with two forms of monomeric fibrin differing in the degree of activation].
Chiriat'ev EA; Leonova OP; Byshevskiĭ ASh
Ukr Biokhim Zh (1978); 1989; 61(1):3-9. PubMed ID: 2741239
[TBL] [Abstract][Full Text] [Related]
16. Usefulness of fibrinopeptide A generation tests in experimental and clinical studies with low molecular weight heparin fractions.
Emanuele RM; Fareed J; Walenga JM; Hoppensteadt DA; Baker WH
Semin Thromb Hemost; 1985 Apr; 11(2):121-8. PubMed ID: 4035363
[TBL] [Abstract][Full Text] [Related]
17. [Kinetic study of the batroxobin-catalyzed release of fibrinopeptide A from human fibrinogen].
Watanabe S; Ohzeki F; Mori N; Mihashi S; Baba S
Yakugaku Zasshi; 1985 Apr; 105(4):395-400. PubMed ID: 3894618
[No Abstract] [Full Text] [Related]
18. [Properties of 2 fibrin monomer species which differ in the degree of thrombin activation. Characteristics of successively appearing active sites].
Lugovskoĭ EV; Gogolinskaia GK; Derzskaia SG; Belitser VA
Biokhimiia; 1978 Jun; 43(6):1045-53. PubMed ID: 667211
[TBL] [Abstract][Full Text] [Related]
19. Radioimmunoassays of human fibrinopeptides A and B.
Budzyński AZ; Marder VJ
Pol Arch Med Wewn; 1978 Jan; 59(1):43-8. PubMed ID: 349523
[No Abstract] [Full Text] [Related]
20. Fibrinopeptide A release by factor-IX concentrates and FEIBA fraction (factor eight inhibitor bypassing activity).
Hofmann V; Straub PW
Thromb Res; 1980 Dec 1-15; 20(5-6):623-31. PubMed ID: 6785894
[No Abstract] [Full Text] [Related]
[Next] [New Search]
